• For investors considering whether Elevance Health at around US$374.71 represents an opportunity or already reflects its quality, this article focuses on what the numbers indicate about value.
• The stock has seen mixed returns, with a 23.8% gain over the last 30 days, a 5.8% return year to date, and a 1-year return of an 8.3% decline.
• Recent coverage of Elevance Health has focused on its position as a major US health insurer and how ongoing shifts in healthcare spending and policy are influencing investor sentiment. Commentary has also highlighted how large managed care companies are being reassessed by the market as investors weigh long-term demand for healthcare services against changing cost and regulatory pressures.
• Elevance Health currently has a valuation score of 5 out of 6. The remainder of this article will break down what that means across different valuation methods and then outline a more comprehensive way to think about valuation at the end.

Approach 1: Elevance Health Discounted Cash Flow (DCF) Analysis

The Discounted Cash Flow model estimates what a stock could be worth by projecting future cash flows and discounting them back to today, so you can compare that value with the current share price.

For Elevance Health, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $6.3b. Analyst estimates and extrapolations extend out to 2035, with projected free cash flow for 2030 of $8.8b. Simply Wall St applies its own extrapolation beyond the analyst horizon, using growth estimates for the later years in the forecast period.

Bringing all those projected cash flows back to today results in an estimated intrinsic value of about $1,047.54 per share. Compared with the current share price of roughly $374.71, the model implies a 64.2% discount. This indicates that Elevance Health stock is trading well below this DCF estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Elevance Health is undervalued by 64.2%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Approach 2: Elevance Health Price vs Earnings

For profitable companies, the P/E ratio is a useful way to see how much you are paying for each dollar of earnings. It is simple, widely used and ties directly to what ultimately matters for shareholders, the company’s ability to generate profit.

What counts as a “normal” or “fair” P/E depends on how the market views a company’s growth prospects and risk profile. Higher expected earnings growth or lower perceived risk tends to support a higher P/E, while slower growth or higher risk usually lines up with a lower multiple.

Elevance Health currently trades on a P/E of 15.52x. This compares with the Healthcare industry average P/E of about 22.38x and a peer group average of 35.31x. Simply Wall St also calculates a proprietary “Fair Ratio” of 31.58x for Elevance Health, which is the P/E that would typically be expected given factors such as the company’s earnings growth, profit margins, industry, market cap and risk profile.

The Fair Ratio is more tailored than a simple peer or industry comparison because it adjusts for these company specific fundamentals rather than assuming one size fits all. Set against the current P/E of 15.52x, the Fair Ratio of 31.58x suggests Elevance Health trades at a considerable discount to this metric based view of fair value.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Elevance Health Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St’s Community page give you a clear story behind the numbers by linking your view of Elevance Health’s future revenue, earnings and margins to a forecast and a Fair Value. These update automatically when fresh news or earnings arrive and help you decide whether the current price looks high or low relative to that Fair Value. This is why some investors might back a more optimistic Elevance Health Narrative with a Fair Value around US$442 per share, while others prefer a more cautious Narrative closer to US$331 per share, with both sitting alongside a consensus-style view around US$388 per share.

For Elevance Health, here are previews of two leading Elevance Health Narratives to make comparison easier:

Fair Value: US$390.54

Implied discount vs last close: around 4.1%

Assumed revenue growth: 6.79%

• Views the stock as priced below its own Fair Value estimate, with the P/E level framed as lower than sector ranges in the supporting assumptions.
• Emphasizes Medicare Advantage, value based care and digital health as supports for the revenue and margin outlook, alongside a diversified mix across commercial, Medicare and Medicaid.
• Flags Medicaid membership pressures, cost inflation, debt levels and regulatory shifts as key risks that need to be watched closely against this more optimistic setup.

Fair Value: US$331.00

Implied premium vs last close: around 13.2%

Assumed revenue growth: 0.70%

• Anchors on a Fair Value that sits well below the current share price and below the analyst consensus target, reflecting a cautious stance on what the current price already assumes.
• Highlights elevated medical costs in ACA and Medicaid lines, slower rate realignment and heavier exposure to government backed plans as ongoing margin headwinds.
• Points to regulatory uncertainty, provider bargaining power and execution risks around acquisitions and value based care as factors that could keep earnings and the future P/E multiple under pressure.

If you want to see how other investors are connecting these bullish and bearish setups with the DCF and multiples work shown above, it is worth reviewing the wider set of Elevance Health narratives and risk checks before making any portfolio decisions. To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Elevance Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Elevance Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.